The female infertility market is set to experience moderate growth, expanding from $1.6 billion in 2023 to $2.3 billion by 2033, with a compound annual growth rate (CAGR) of 3.5% across the seven major markets (7MM) — the US, France, Germany, Italy, Spain, the UK, and Japan. This forecast is detailed in GlobalData’s report, “Female Infertility: Seven Market Drug Forecast and Market Analysis.
The anticipated growth is primarily driven by an increasing number of women delaying pregnancy until later in life, when fertility naturally declines. Additionally, the introduction of new therapies during the forecast period, such as Kissei Pharmaceutical’s linzagolix choline, IBSA Institut Biochimique’s subcutaneous progesterone, and Ferring Pharmaceuticals’ Menopur (menotropin), is expected to contribute to market expansion. Despite this, the market remains dominated by off-label therapies, with many drugs used in fertility treatments initially intended for breast cancer and other gynecological disorders. This situation presents significant challenges for the introduction of novel therapies.
Current treatments for female infertility have seen little innovation, with Merck Sereno’s Gonal-F remaining the leading drug, forecasted to generate $713 million in sales by 2033. Interviews with key opinion leaders (KOLs) by GlobalData reveal a moderate level of unmet need in the market. Simplifying the in vitro fertilization (IVF) process, particularly through improvements in drug administration and dosing frequency, is seen as highly desirable.
Among the 7MM markets, the US is the largest contributor to the female infertility sector, expected to account for 58.5% of sales in 2023 and 66.0% by 2033. This dominance is attributed to the higher cost of therapeutics in the US and the higher prevalence of female infertility. Conversely, Spain is anticipated to contribute the least, with only 4.5% of the market share in 2023 and a projected 4% by 2033.
Related topics:
